← All trials
NCT05091619
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 22, 2021
- Primary completion
- Apr 22, 2023
- Completion date
- Sep 22, 2027
- First posted
- Oct 25, 2021
- Last posted
- Oct 27, 2021
- Enrollment
- 2898
- Arms / groups
- 9 / —
- Source
- AACT · ingestion pipeline
Sponsors
- China National Biotec Group Co., LtdLead sponsor
- Government of ChinaOverall official - principal investigator
- Beijing Tiantan Bio Co., LtdCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.